Literature DB >> 30907933

Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018.

Inmaculada Hernandez1, Chester B Good2, William H Shrank2,3, Walid F Gellad4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30907933      PMCID： PMC6487544          DOI： 10.1001/jama.2019.2990

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Why is there no generic insulin? Historical origins of a modern problem.

Authors:  Jeremy A Greene; Kevin R Riggs
Journal:  N Engl J Med       Date:  2015-03-19       Impact factor: 91.245

2.  Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors.

Authors:  Alvaro San-Juan-Rodriguez; Max V Prokopovich; William H Shrank; Chester B Good; Inmaculada Hernandez
Journal:  JAMA Intern Med       Date:  2019-05-01       Impact factor: 21.873

3.  Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014.

Authors:  Jing Luo; Jerry Avorn; Aaron S Kesselheim
Journal:  JAMA Intern Med       Date:  2015-10       Impact factor: 21.873

4.  Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002-2013.

Authors:  Xinyang Hua; Natalie Carvalho; Michelle Tew; Elbert S Huang; William H Herman; Philip Clarke
Journal:  JAMA       Date:  2016-04-05       Impact factor: 56.272
  4 in total
  8 in total

1.  Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia.

Authors:  Yazed AlRuthia; Ohud H Bahari; Suliman Alghnam; Ali M Alrumaih; Hassan Asiri; Mohammed Alshammari; Mansour Alhowimel; Hana A Al-Abdulkarim
Journal:  Front Public Health       Date:  2022-06-13

2.  Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.

Authors:  Alexandra Glynn; Inmaculada Hernandez; Eric T Roberts
Journal:  Health Serv Res       Date:  2022-04-27       Impact factor: 3.734

3.  Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018.

Authors:  Karen Van Nuys; Rocio Ribero; Martha Ryan; Neeraj Sood
Journal:  JAMA Health Forum       Date:  2021-11-05

Review 4.  Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin.

Authors:  Jing Luo; Walid F Gellad
Journal:  Curr Diab Rep       Date:  2020-01-29       Impact factor: 5.430

5.  Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020.

Authors:  Sudipa Sarkar; James Heyward; G Caleb Alexander; Rita R Kalyani
Journal:  JAMA Netw Open       Date:  2021-10-01

6.  Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.

Authors:  Inmaculada Hernandez; Walid F Gellad
Journal:  J Manag Care Spec Pharm       Date:  2020-02

7.  A Decade of Disparities in Diabetes Technology Use and HbA1c in Pediatric Type 1 Diabetes: A Transatlantic Comparison.

Authors:  Ananta Addala; Marie Auzanneau; Kellee Miller; Werner Maier; Nicole Foster; Thomas Kapellen; Ashby Walker; Joachim Rosenbauer; David M Maahs; Reinhard W Holl
Journal:  Diabetes Care       Date:  2020-09-16       Impact factor: 19.112

8.  Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition.

Authors:  Alvaro San-Juan-Rodriguez; Walid F Gellad; Chester B Good; Inmaculada Hernandez
Journal:  JAMA Netw Open       Date:  2019-12-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.